FOXL2 Recombinant Rabbit Monoclonal Antibody [JE38-52] (HA721558)

UNIPROT #

P58012

PROTEIN NAME

FOXL2

SYNONYMS

Blepharophimosis antibody;Blepharophimosis epicanthus inversus and ptosis 1 antibody;Blepharophimosis epicanthus inversus and ptosis antibody;BPES 1 antibody;BPES antibody;BPES1 antibody;Epicanthus inversus and ptosis 1 antibody;Forkhead box L2 antibody;Forkhead box protein L2 antibody;Forkhead transcription factor FOXL2 antibody;FOX L2 antibody;FOXL 2 antibody;FOXL2 antibody;FOXL2_HUMAN antibody;PFRK antibody;PINTO antibody;PITUITARY FORKHEAD FACTOR antibody;POF 3 antibody;POF3 antibody

SUBCELLULAR LOCATION

Nucleus.

FUNCTION

Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis throught transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. Defects in FOXL2 are a cause of blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]; also known as blepharophimosis syndrome. It is an autosomal dominant disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold running inward and upward from the lower lid. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.